Sydney Stewart, Author at BioTuesdays

Markets

ContraVir Pharma receives positive NASDAQ listing decision

The Nasdaq Hearings Panel granted ContraVir Pharmaceuticals’ (NASDAQ:CTRV) request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions.

May 6, 2019

Developments

EyePoint presents YUTIQ 36-month follow up Phase 3 data at ARVO

EyePoint Pharmaceuticals (NASDAQ:EYPT) presented 36-month efficacy and safety data supporting its YUTIQ three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the...

May 1, 2019

Developments

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Akari Therapeutics (NASDAQ:AKTX) reported positive results from the first three bullous pemphigoid (BP) patients in an ongoing Phase 2 clinical trial. BP is a severe orphan inflammatory skin disease characterized by...

April 23, 2019

Developments

Alder BioPharma BLA for eptinezumab accepted by FDA

Alder BioPharma (NASDAQ:ALDR) BLA application for eptinezumab, a monoclonal antibody for the prevention of migraines, has been accepted by the FDA. Administered intravenously, eptinezumab targets and suppresses...

April 23, 2019

Developments

BriaCell in publication at ASCO, presentation at breast cancer meeting

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...

April 23, 2019

Developments

NeuroSigma to market first medical device for ADHD treatment

Privately-held NeuroSigma has received FDA approval to market its Monarch external Trigeminal Nerve Stimulation (eTNS) System to attention deficit hyperactivity disorder (ADHD) patients. Indicated in patients from...

April 22, 2019

Developments

Canopy Growth secures right to acquire U.S. cannabis operator Acreage Holdings

Canopy Growth (TSX:WEED; NYSE:CGC) entered a complex arrangement to acquire Acreage Holdings (CSE:ACGR; OTC:ACRGF; FSE:0ZV) when cannabis production and sale becomes federally legal in the U.S.

April 18, 2019

Executive Moves

Imagin Medical adds world-renowned bladder cancer expert Dr. Ashish Kamat to SAB

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) named Dr. Ashish Kamat to its scientific advisory board.

April 17, 2019

Developments

Profound Medical announces first-of-its-kind TULSA-PRO installation

Profound Medical (TSX:PRN; OTCQX:PRFMF) announced the first prostate cancer treatment using a first-of-its-kind TULSA-PRO installation in Trier, Germany. The installation combines Profound’s TULSA-PRO system with...

April 16, 2019

Developments

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...

April 12, 2019

Author - Sydney Stewart

ContraVir Pharma receives positive NASDAQ listing decision

EyePoint presents YUTIQ 36-month follow up Phase 3 data at ARVO

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Alder BioPharma BLA for eptinezumab accepted by FDA

BriaCell in publication at ASCO, presentation at breast cancer meeting

NeuroSigma to market first medical device for ADHD treatment

Canopy Growth secures right to acquire U.S. cannabis operator Acreage Holdings

Imagin Medical adds world-renowned bladder cancer expert Dr. Ashish Kamat to SAB

Profound Medical announces first-of-its-kind TULSA-PRO installation

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Subscribe